Pacific Biosciences of California, Inc., (NASDAQ:PACB) a pioneer
and leader in long-read sequencing using Single Molecule, Real-Time
(SMRT®) Technology, today announced that its technology will be
featured in 36 presentations at next week's American Society of
Human Genetics (ASHG) 2015 annual meeting taking place in
Baltimore, Maryland.
The company will also display its new instrument, the Sequel™
System, which was launched yesterday. The Sequel System provides
higher throughput, more scalability, a reduced footprint and lower
sequencing project costs compared to the PacBio® RS II System,
while maintaining the existing benefits of the company's SMRT
Technology.
"We are excited to support the human genetics community as they
pursue the generation of higher-quality whole human genomes, and
move beyond SNPs to sequence the full size-spectrum of human
genetic variation," said Jonas Korlach, Chief Scientific Officer of
Pacific Biosciences. "With the introduction of our Sequel platform,
SMRT Sequencing will be available to more scientists seeking to
find the underlying heritability of genetic diseases."
The company will host a workshop titled "Addressing Hidden
Heritability through Long-Read Single Molecule, Real-Time (SMRT)
Sequencing" on Wednesday, October 7 from 1-2:30 p.m. Eastern Time
at the Sheraton Inner Harbor Hotel, Baltimore. The event will be
hosted by Michael Hunkapiller and Jonas Korlach from Pacific
Biosciences, and include talks by Richard Gibbs from Baylor College
of Medicine and Richard Wilson from Washington University in St.
Louis. Those attending the conference in Baltimore can register
here. The company will also offer LIVE streaming and access to the
recording; for more information, click here.
The depth and breadth of scientific talks presented at ASHG this
year demonstrate how long-read SMRT Sequencing is opening up new
frontiers by helping the genome sequencing community create
gold-standard genome references, characterize complex regions,
resolve structural variation, and unlock isoform diversity.
Highlights include the following podium presentations:
Wednesday, October 7 at 2:30 p.m. Long read single-molecule
real-time (SMRT) full gene sequencing of cytochrome P450 2D6
(CYP2D6) #27 Y. Yang, Icahn School of Medicine at Mount Sinai
Wednesday, October 7 at 3:15 p.m. Comprehensive genome and
transcriptome structural analysis of a breast cancer cell line
using PacBio long read sequencing #14 M. Nattestad, Cold Spring
Harbor
Wednesday, October 7 at 3:30 p.m. Evolution and structural
diversity of the complement factor H related gene cluster #47 S.
Cantsilieris, University of Washington School of Medicine
Friday, October 9 at 2:15 p.m. Building a platinum assembly from
single haplotype human genomes generated from long molecule
sequencing #227 K. Meltz Steinberg, Washington University
Friday, October 9 at 2:30 p.m. Building a Better Human Genome
Reference and Targeting Structure using SingleMoleculeTechnologies
#228 R. Sebra, Icahn School of Medicine at Mount Sinai
Friday, October 9 at 2:45 p.m. Genome in a Bottle: You may have
sequenced, but how well did you do? #229 J.M. Zook, National
Institute of Standards and Technology
Friday, October 9 at 3:30 p.m. A Diploid Personal Human Genome
Reference from Diverse Sequence Data – A Model for Better Genomes
#232 K.C. Worley, Baylor College of Medicine
Saturday, October 10 at 10:45 p.m. Full-length mRNA sequencing
uncovers a widespread coupling between transcription and mRNA
processing #71 S.Y. Anvar, Leiden University Medical Center
Research conducted using SMRT Sequencing will also be featured
in at least 28 poster presentations. A full list of PacBio-related
ASHG meeting research and activities is available here. Attendees
can also visit the PacBio booth (#907).
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers
sequencing systems to help scientists resolve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT®)
Technology, Pacific Biosciences' products enable: de novo genome
assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and DNA base modification
identification to help characterize epigenetic regulation and DNA
damage. Pacific Biosciences' technology provides the industry's
highest consensus accuracy over the longest read lengths in
combination with the ability to detect real-time kinetic
information. The Sequel System, including consumables and software,
provides a simple, fast, end-to-end workflow for SMRT
Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to the attributes of the Sequel System, future
commercialization, uses and performance of the company's products,
and other future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences' control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences' most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption "Risk Factors." Pacific
Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
CONTACT: For Pacific Biosciences:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2024 to May 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From May 2023 to May 2024